

Cholesterol, Statins and the Truth about Cardiovascular Health and Disease

By Donald R. Yance

References:

1. Smith, Sidney C., Heart disease prevention must get more attention, *World Heart Federation, Circulation*, 30/06/2004
2. Kuller, Lewis Dr., *Circulation*
3. Graboys, et. al. 1987 *Journal of the American Medical Association*; Graboys, et. al. 1992 *Journal of the American Medical Association*; Coronary Artery Surgery Study (CASS) 1984 *New England Journal of Medicine*; CASS study, Alderman, et. al. 1982 and 1990 *Circulation*.
4. Becker, Diane, Hidden Stress Underlies Heart Attacks, Study Shows, Yahoo News, Johns Hopkins University in Baltimore, November 11, 2003
5. *Arterioscler Thromb Vasc Biol.* 2004 Mar;24(3):498-503. Epub 2004 Jan 22, Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Silaste ML, Rantala M, Alfthan G, Aro A, Witztum JL, Kesaniemi YA, Horkko S. Department of Internal Medicine and Biocenter Oulu, University of Oulu, Finland. Marja-Leena.Silaste@oulu.fi
6. Enig, Mary G, PhD, *Trans Fatty Acids in the Food Supply: A Comprehensive Report Covering 60 Years of Research*, 2nd Edition, Enig Associates, Inc, Silver Spring, MD, 1995, 4-8.
7. Fang, Dr Jing Exercise: a key factor for lowering risk of heart disease, *American Journal of Preventive Medicine*, 5/11/2003, Albert Einstein College of Medicine in New York
8. *Science Blog* November 4, 2003
9. Rifai N, Ridker PM, Inflammatory markers and coronary heart disease. *Curr Opin Lipidol* 2002 Aug;13(4):383-9.
10. Albert CM, et al, Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation* 2002 Jun 4;105 (22):2595-9.
11. Bermudez EA, Ridker PM, C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. *Prev Cardiol* 2002 Winter;5(1):42-6.
12. Blake GJ, Ridker PM, Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. *Ital Heart J* 2001 Nov;2(11):796-800.
13. Osiecki HE. The role of chronic inflammation in cardiovascular disease and its regulation by nutrients. *Altern Med Rev.* 2004 Mar;9(1):32-53
14. *Journal of the Amer. College of Nutrition* 1993;(1)12: 2-13
15. Coombes R. Heart disease. Researchers give eggs a break. , *Nurs Times.* 2000 Jul 13-19;96(28):13.
16. McNamara DJ. Eggs and heart disease risk: perpetuating the misperception. *Am J Clin Nutr.* 2002 Feb;75(2):333-5
17. Horrocks LA, Yeo YK, *Lipids*, 1999; 34 (suppl) S313.39065
18. Fernandez, ML, Eggs have no impact on dangerous cholesterol, new study, *Metabolism* (vol 5, issue 6, pp 823-830) 28/06/2004, University of Connecticut
19. Chen, Junshi, *Diet, Life-Style and Mortality in China: A Study of the Characteristics of 65 Chinese Counties*, Cornell University Press, Ithica, NY
20. Lackland, D T, et al, *J Nutr*, Nov 1990, 120:11S:1433-1436, *Nutr Week*, Mar 22, 1991, 21:12:2-3
21. Alfin-Slater, R B, and L Aftergood, "Lipids," *Modern Nutrition in Health and Disease*, 6th ed, R S Goodhart and M E Shils, eds, Lea and Febiger, Philadelphia, 1980, 131 Smith, M M, and F Lifshitz, *Pediatrics*, Mar 1994, 93:3:438-443
22. *Journal of the American Dietetic Association* 2002;102:52-57
23. Gittleman, Ann Louise, MS, *Beyond Pritikin*, 1980, Bantam Books, New York, NY
24. Brunner J. Parhofer KG. Schwandt P. Bronisch T. Dr. J. Brunner, Max Planck Institute of Psychiatry, Kraepelinstra[latin sharp s]e 10, 80804 Munich; Germany. E-Mail: jbrunner@mpipsykl.mpg.de. Cholesterol, essential fatty acids, and suicide. *Pharmacopsychiatry.* Vol 35(1) (pp 1-5), 2002.
25. *Psychosomatic Medicine* 2000;62.
26. *Annals of Internal Medicine* (1998;128(6):478-487); *The Journal of the American Medical Association* (1997;278:313-321)
27. *Journal of the American Geriatrics Society* April 1999;47:402-406
28. Silaste ML, Rantala M, Alfthan G, Aro A, Witztum JL, Kesaniemi YA, Horkko S. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). *Arterioscler Thromb Vasc Biol.* 2004 Mar;24(3):498-503. Epub 2004 Jan 22 Department of Internal Medicine and Biocenter Oulu, University of Oulu, Finland. Marja-Leena.Silaste@oulu.fi

29. West, Sheila G. Nuts about cardiovascular health, American Heart Association's 5th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology in San Francisco 13/05/2004
30. Kurowska, Dr Elzbieta, Citrus peel shows cholesterol-lowering qualities, *Journal of Agricultural and Food Chemistry*, 12/05/2004
31. David Heber, George Blackburn, Vay Liang Go, Nutritional Oncology, Academic Press, 1999, Chapter 22. *Cancer Chemoprevention*, pg. 351
32. Sesso, Dr, Further evidence to link lycopene with heart disease protection, *American Journal of Clinical Nutrition*, vol 79, no1, 47-53, 28/01/2004)
33. Inoue T, Matsunaga R, Sakai Y, Yaguchi I, Takayanagi K, Morooka S. Insulin resistance affects endothelium-dependent acetylcholine-induced coronary artery response., *Eur Heart J*. 2000 Jun;21(11):895-900.
34. Mckeown NM, Meigs JB, et al, *Am J Clin Nutr*, 2002;76:390-398. (Addressw: Paul F. Jacques, E-mail: paul@hnrc.tufts.edu) 39656
35. Liu S. *J Am Coll Nutr*, 2002; 21 (4):298-306. (Address: Simin Liu, MD, ScD, E-mail: sluu@rics.bwh.harvard.edu) 39700
36. *JAMA* January 1, 2003;289:76-79
37. Vincenza Snow, MD; Mark D. Aronson, MD; E. Rodney Hornbake, MD; Christel Mottur-Pilson, PhD; and Kevin B. Weiss, MD, the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians, *Annals of Internal Medicine* April 20, 2004;140: 644-649
38. 'Experts' Recommend Higher Doses of Cholesterol Drugs, *New England Journal of Medicine* March 8, 2004
39. Ballantyne CM. Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety. *Am J Cardiol*. 2003 Aug 21;92(4B):3K-9K.
40. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA*. 2002 Dec 18;288(23):2998-3007
41. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA, Connelly PW. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. *JAMA*. 2003 Jul 23;290(4):502-10
42. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. *JAMA*. 2003 Apr 2;289(13):1681-90.
43. Phillips PS, Haas RH. Statin-associated myopathy with normal creatine kinase levels. *Ann Intern Med*. 2003 Jun 17;138(12):1008-9. Scripps Mercy Hospital; San Diego, CA 92103
44. Jamil S, Iqbal P. Rhabdomyolysis induced by a single dose of a statin. *Heart*. 2004 Jan;90(1):e3. Medical Directorate, Chesterfield and North Derbyshire Royal Hospital NHS Calow, Chesterfield, UK
45. Walsh, Kenneth, Simons, Michael Drugs Stimulate Growth of New Blood Vessels By Mimicking Growth Factor, *Nature Medicine* September, 2000;6:965-966, 1004-1010, Tufts University School of Medicine in Boston, Massachusetts, Beth Israel Deaconess Medical Center in Boston
46. Pahor M. Carcinogenicity of lipid-lowering drugs. *JAMA*. 1996 May 15;275(19):1480; author reply 1481-2; Illingworth R. Carcinogenicity of lipid-lowering drugs. *JAMA*. 1996 May 15;275(19):1479-80; author reply 1481-2; Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA*. 1996 Jan 3;275(1):55-60
47. Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y, Sugimachi K., Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues, *Br J Cancer*. 2000 Oct;83(7):887-91
48. Shinoda K, Ishida S, Kawashima S, Wakabayashi T, Uchita M, Matsuzaki T, Takayama M, Shinmura K, Yamada M. Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. *Curr Eye Res*. 2000 Aug;21(2):655-61
49. Loscalzo J, Weinfeld M, Fless GM, et al. Lipoprotein(a), fibrin binding, and plasminogen activation. *Arteriosclerosis* 1990; 10:240-245.
50. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. *Arch Intern Med* 1997; 157:1170-1176
51. Lahiri DK. Apolipoprotein e as a target for developing new therapeutics for Alzheimer's disease based on studies from protein, RNA, and regulatory region of the gene. *J Mol Neurosci*. 2004;23(3):225-34
52. Burke JR, Roses AD. Genetics of Alzheimer's disease. *Int J Neurol*. 1991-1992;25-6:41-51.
53. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci U S A*. 1993;90:1977-81.
54. Roses AD, Saunders AM. APOE is a major susceptibility gene for Alzheimer's disease. *Curr Opin Biotechnol*. 1994;5:663-7.
55. Corder EH, Lannfelt L, Bogdanovic N, Fratiglioni L, Mori H. The role of APOE polymorphisms in late-onset dementias. *Cell Mol Life Sci*. 1998;54:928-34.
56. Roses AD. Apolipoprotein E and Alzheimer's disease. The tip of the susceptibility iceberg. *Ann N Y Acad Sci*. 1998;855:738-43

57. Ramassamy C, Averill D, Beffert U, et al. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. *Neurobiol Dis.* 2000;7:23-37
58. Gerdes, LU, Klausen IC, Sihm I, Færgeman O. Apolipoprotein E Polymorphism in a Danish Population Compared to Findings in 45 Other Study Populations Around the World. *Genet Epidemiol* 1992;9:155-67
59. Lahiri DK, Sambamurti K, Bennett DA. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. *Neurobiol Aging.* 2004;25:651-60.
60. Godfrey ME, Wojcik DP, Krone CA. Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity. *J Alzheimers Dis.* 2003;5:189-95
61. Wang XL, Mahaney MC. Genotype-specific effects of smoking on risk of CHD. *Lancet.* 2001;358:115-19
62. Sterling, P., and Eyer, J., Allostasis: a new paradigm to explain arousal pathology. In: S. Fisher and J. Reason, Editors, *Handbook of Life Stress, Cognition and Health*, Wiley, New York (1988), pp. 629–649
63. Manuck, S.B., Kaplan, J.R. Adams, M.R., Clarkson, T.B., Studies of psychosocial influences on coronary artery atherosclerosis in cynomolgus monkeys. *Health Psychol.* 7(1995), pp. 113–124
64. Brindley, D.N., Rolland Y., Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis. *Clin. Sci.* 77 (1989), pp. 453–461.
65. Bartol T. Cardiovascular dysmetabolic syndrome: managing insulin resistance syndrome. Programs and abstracts of the National Conference for Nurse Practitioners 2001; November 7-10, 2001; Baltimore, Maryland. Session 415.
66. Marckmann P, Gronbaek M. Fish consumption and coronary heart disease mortality. A systematic review of prospective cohort studies. *Eur J Clin Nutr* 1999;53: 585-90.
67. Marchioli MD, Roberto Large study shows fish oil supplements reduce sudden cardiac death *Circulation: Journal of the American Heart Association*, April 12, 2002, Consorzio Mario Negri Sud in Santa Maria Imbaro, Italy
68. SoRelle R. Fish Provides Heart-Healthy Benefits for Diabetic Women, *Circulation* March 31, 2003;107:1852
69. Nordoy A. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease. *Minerva Med.* 2002 Oct;93(5):357-63. Department of Medicine, Institute of Clinical Medicine, University of Tromso, Tromso, Norway
70. Henry, Thomas, DHA levels implicated in epilepsy, American Academy of Neurology 04/05/2004, Emory University School of Medicine.
71. Goel HC; Prasad J; Singh S; Sagar RK; Kumar IP; Sinha AK. *Phytotherapy* 2002 Jan;9(1):15-25 (ISSN: 0944-7113) Radioprotection by a herbal preparation of Hippophae rhamnoides, RH-3, against whole body lethal irradiation in mice. Department of Radiation Biology, Institute of Nuclear medicine and Allied Sciences, Delhi, India. radbiol@nda.vsnl.net.in.
72. Suleyman H; Demirezer LO; Buyukokuroglu ME; Akcay MF; Gepdiremen A; Banoglu ZN; Gocer F, Antiulcerogenic effect of Hippophae rhamnoides L. *Phytother Res* 2001 Nov;15(7):625-7 (ISSN: 0951-418X). Ataturk University, Faculty of Medicine, Department of Pharmacology, Erzurum, Turkey.
73. Suleyman H; Gumustekin K; Taysi S; Keles S; Oztasan N; Aktas O; Altinkaynak K; Timur H; Akcay F; Akar S; Dane S; Gul M. Beneficial effects of Hippophae rhamnoides L. on nicotine induced oxidative stress in rat blood compared with vitamin E. *Biol Pharm Bull* 2002 Sep;25(9):1133-6 (ISSN: 0918-6158) Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
74. Kiokias S, Gordon MH. Dietary supplementation with a natural carotenoid mixture decreases oxidative stress, *Eur J Clin Nutr.* 2003 Sep;57(9):1135-40. Hugh Sinclair Unit of Human Nutrition, School of Food Biosciences, The University of Reading, Whiteknights, Reading, UK.
75. Krylova SG, Konovalova ON, Zueva EP., Correction by common sea buckthorn bark and sprout extracts of hormonal and metabolic disturbances during stress in rats, *Eksp Klin Farmakol* 2000 Jul-Aug;63(4):70-3, Institute of Pharmacology, Tomsk Scientific Center, Siberian Division, Russian Academy of Medical Sciences, Russia.
76. Pasquier E, Ratnayake WM, Wolff RL. Effects of delta5 polyunsaturated fatty acids of maritime pine (*Pinus pinaster*) seed oil on the fatty acid profile of the developing brain of rats. *Lipids.* 2001 Jun;36(6):567-74. Nutrition Research Division, Health Products and Food Branch, Health Canada, Ottawa, Ontario.
77. Aleksandrov V.N., Dunin M.S., Vinogradov A.K. Siberian Pine as recourse of Health. Barnaul-S.-Petersburg, 1994, 12p. Kardashev K.P. Siberian Pine Oil. 1993. Gosizdat. 19p.
78. Rush V.A., Lizunova K.A. Physical and chemical characteristic of Siberian Pine Oil. *Food Technology*, 1968, 3, p 7-9.
79. Asset G, Leroy A, Bauge E, Wolff RL, Fruchart JC, Dallongeville J., Effects of dietary maritime pine (*Pinus pinaster*)-seed oil on high-density lipoprotein levels and in vitro cholesterol efflux in mice expressing human apolipoprotein A-I. *Br J Nutr.* 2000 Sep;84(3):353-60.
80. Asset G, Bauge E, Wolff RL, Fruchart JC, Dallongeville J. *J Nutr.* 1999 Nov;129(11):1972-8. Pinus pinaster oil affects lipoprotein metabolism in apolipoprotein E-deficient mice. INSERM U-325, 59019 Lille, France.
81. Asset G, Staels B, Wolff RL, Bauge E, Madj Z, Fruchart JC, Dallongeville J. Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat. *Lipids.* 1999 Jan;34(1):39-44. INSERM U-325 and Departement d'Atherosclerose, Institut Pasteur de Lille, France.

82. Sanders TA. Nutrition Food and Health Research Centre, King's College London (University of London), Franklin-Wilkins Building, 150 Stamford Street, London SE1 8WA. Olive oil and the Mediterranean diet. *International Journal for Vitamin & Nutrition Research*. 71(3):179-84, 2001 May
83. Medeiros, Denis M. *Handbook of Nutraceuticals and Functional Foods*, CRC Press, Boca Raton, FL, Chapter 15, Olive oil and Health Benefits pg. 261-69
84. Thompson Coon JS, Ernst E. Herbs for serum cholesterol reduction: a systematic view. *J Fam Pract*. 2003 Jun;52(6):468-78. Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, 25 Victoria Park Road, Exeter EX2 4NT, United Kingdom. jo.thompson-coon@pms.ac.uk
85. Wang X, Greilberger J, Ledinski G, Kager G, Paigen B, Jurgens G. The hypolipidemic natural product Commiphora mukul and its component guggulsterone inhibit oxidative modification of LDL. *Atherosclerosis*. 2004 Feb;172(2):239-46.
86. Verna SK and Bordia A, Effect of Commiphora mukul resin (gumguggul) in patients of hyperlipidemia with special reference to HDL. *Ind. J Med. Res.* 87: 356-60,1988
87. Man RY, Lynn EG, Cheung F, Tsang PS, O K. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). *Mol Cell Biochem*. 2002 Apr;233(1-2):153-8.
88. Journoud M. Jones PJH., Red yeast rice: A new hypolipidemic drug. *Life Sciences*. Vol. 74(22)(pp 2675-2683), 2004.) P.J.H. Jones, Sch. of Dietetics and Hum. Nutrition, Fac. of Agric. And Environ. Sciences, McGill University, 111 Lakeshore Road, Montreal, QC H9X 3V9; Canada. E-Mail: jonesp@macdonald.mcgill.ca.
89. *Townsend Letter for Doctors and Patients*, Detox Support, p. 45, October 2002
90. Sinclair, Hugh, Artichoke leaf extract under study for cholesterol-lowering, 17/03/2004, University of Essen, UK
91. Gupta A., Gupta R., Lal B., Institution Jaipur Diabetes and Research Centre. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. *Journal of the Association of Physicians of India*. 49:1057-61, 2001 Nov.
92. Sur P. Das M, Gomes A, et al., Trigonella foenum (Fenugreek) seed extract as an antineoplastic agent, *Phytotherapy Res*. 2001;15:257-59
93. Hibasami H, Moteki H, Ishikawa K, et al. *Int J Mol Med* 2003;11:23-26. Protodioscin isolated from fenugreek (*Trigonella foenumgraecum* L.) induces cell death and morphological change indicative of apoptosis in leukemic cell line H-60, but not in gastric cancer cell line KATO III.
94. Tokunaga S et al, 2002, Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan, *Annals of Epidemiology*, Apr;12(3):157-65
95. Tokunaga S; White IR; Frost C; Tanaka K; Kono S; Tokudome S; Akamatsu T; Moriyama T; Zakouji H, Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. *Ann Epidemiol* 2002 Apr;12(3):157-65 (ISSN: 1047-2797) Department of Preventive Medicine, Graduate School of Medical School of Medical Sciences, Kyushu University, Fukuoka, Japan. Toksan@phealth.med.kyushu-u.ac.jp.
96. Kono S, Shinchi K, Ikeda N, et al. Green tea consumption and serum lipid profiles: A cross-sectional study in Northern Kyushu, Japan. *Prev Med* 1992;21:526-531.
97. Yamaguchi Y, Hayashi M, Yamazoe H, et al. Preventive effects of green tea extract on lipid abnormalities in serum, liver and aorta of mice fed an atherogenic diet. *Nip Yak Zasshi* 1991;97(6):329-337.
98. Sagesaka-Mitane Y, Milwa M, Okada S. Platelet aggregation inhibitors in hot water extract of green tea. *Chem Pharm Bull* 1990;38(3):790-793.
99. Stensvold I, Tverdal A, Solvoll K, et al. Tea consumption. Relationship to cholesterol, blood pressure, and coronary and total mortality. *Prev Med* 1992;21:546-553
100. Mas R, et al. 1999. "Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors." *Clin Pharmacol Ther* 65:439-47
101. Arruzazabaia ML, et al, 2000. "Protective effects of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. *Braz J Med Biol Res* 33:835-40
102. Moghadasian MH, Frohlich JJ. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. *Amer. Journal of Medicine* 1999; 588-94
103. Oligomeric proanthocyanidin complexes: history, structure, and phytopharmaceutical applications. *Altern Med Rev* 2000 Apr;5(2):144-51. International Clinical Research Center, Scottsdale, AZ 85260, USA
104. Folts, John D. Ph.D., a researcher presenting data at Experimental Biology, 2001, the annual meeting of the Federation of the American Societies of Experimental Biology (FASEB), Orlando, April 1, 2002/PR Newswire
105. Araim O, Ballantyne J, Waterhouse AL, Sumpio BE., Inhibition of vascular smooth muscle cell proliferation with red wine and red wine polyphenols. *J Vasc Surg*. 2002 Jun;35(6):1226-32.
106. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. *Lancet*. 1993 Apr 24;341(8852):1103-4
107. Kobayashi M, Ishida Y, Shoji N, Ohizumi Y. Cardiotoxic action of [8]-gingerol, an activator of the Ca⁺⁺-pumping adenosine triphosphatase of sarcoplasmic reticulum, in guinea pig atrial muscle. *J Pharmacol Exp Ther* 1988; 246:667-73.

108. Srivastava KC. Aqueous extracts of onion, garlic and ginger inhibit platelet aggregation and alter arachidonic acid metabolism. *Biomed Biochim Acta* 1984; 43:S335-46.
109. Backon J. Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry. *Med Hypotheses* 1986; 20:271-8.
110. Srivastava KC. Isolation and effects of some ginger components of platelet aggregation and eicosanoid biosynthesis. *Prostaglandins Leukot Med* 1986; 25:187-98.
111. Guh J-H, Ko F-N, Jong T-T, Ting C-M. Antiplatelet effect of gingerol isolated from *Zingiber officinale*. *J Pharmacy Pharmacology* 1995; 47:329-32.
112. Facchinetti F, Neri I, Tarabusi M, F. Facchinetti, (2002), Eleutherococcus senticosus reduces cardiovascular stress response in healthy subjects: A randomized, placebo-controlled trial. *Stress & Health*. Vol 18(1) pp 11-17
113. Maslova LV. et al. (1994) "The cardioprotective and antiadrenergic activity of an extract of *Rhodiola rosea* in stress" *Eksp Klin Farmakol* 57(6): 61-6, The effect of *Rhodiola* capsules on oxygen consumption of myocardium and coronary artery blood flow in dogs *Zhongguo Zhong Yao Za Zhi* 1998 Feb;23(2):104-6, inside back cover
114. Zhang Z; Liu J; Shang X; Yang J; Chu J; Wang Z; Yao Z; Ma H; Li Q; Wang Y Institute of Information on TCM, China Academy of Traditional Chinese Medicine, Beijing 100700
115. Wojcicki, J. Samochoiewicz, L., Kadlubowsky, D. Lutomski, J. 1977, Studies on the Saponin fraction from the root of *Aralia Mandchurica* (Rupr. et Maxim), *Herba Polonica*, 4, p.285-288
116. Yuan CS; Attele AS; Wu JA, 1999, *Panax quinquefolium* L. inhibits thrombin-induced endothelin release in vitro, *American Journal of Clinical Medicine*;27(3-4):331-8
117. Toda, N., K. Ayajiki, et al. (2001). "Ginsenoside potentiates NO-mediated neurogenic vasodilation of monkey cerebral arteries." *Journal of Ethnopharmacology* 76: 109-113
118. Friedl R; Moeslinger T; Kopp B; Spieckermann PG, Stimulation of nitric oxide synthesis by the aqueous extract of *Panax ginseng* root in RAW 264.7 cells., *Br J Pharmacol* 2001 Dec;134(8):1663-70, Institute for Physiology, Schwarzsplanierstrasse 17, 1090 Vienna, Austria.
119. Wu S-F, Sui D-Y, Yu X-F, Lu Z-Z, Zhao X-Z., S.-F. Wu, Department of Pharmacology, Bethune Medical University, Changchun 130021; China, Antimyocardial ischemic effects of *Panax quinquefolium* 20 s-protopanaxdiol saponins (PQDS) and its mechanism, *Chinese Pharmaceutical Journal*. Vol 37(2) (pp 100-103), 2002
120. Plotnikov MB, Aliev OI, Vasil'ev AS, Maslov MIU, Dmitruk SE, Krasnov EA. Laboratory of Circulatory. Effect of *Rhaponticum carthamoides* extract on hemorheological properties of blood in rats with arterial hypertension, Tomsk Institute of Pharmacology, Tomsk Scientific Center, Siberian Division, Russian Academy of Medical Sciences, pr. Lenina 3, Tomsk, 634028 Russia. Article in Russian
121. Maimeskulova LA, Maslov LN. Laboratory of Experimental Cardiology, Siberian Division of the Russian Academy of Medical Sciences, Tomsk, Russia. "Anti-arrhythmic effect of phytoadaptogens." *Eksp Klin Farmakol* 2000 Jul-Aug;63(4):29-31, *Rhaponticum uniflorum* a close relative of RC inhibits lipid peroxidation and is antiatherosclerotic
122. Zhang, Y.-H., J.-K. Cheng, et al. (2002). "Triterpenoids from *Rhaponticum uniflorum*." *Journal of the Chinese Chemical Society* 49: 117-124.
123. Li, P.C., et al., "Schisandra chinensis-dependent myocardial protective action of sheng-mai-san in rats," *Am J Chin Med* (1996), 24(3-4):255-62
124. Jones K. Reishi mushroom: Ancient medicine in modern times. *Alt Compl Ther* 1998;4:256-66 X
125. Kammatsuse K, Kajiwara N, Hayashi K. Studies on *Ganoderma lucidum*: I. Efficacy against hypertension and side effects. *Yakugaku Zasshi* 1985;105:531-3
126. Jin H, Zhang G, Cao X, et al. Treatment of hypertension by ling zhi and its effects on arterial, arteriolar and capillary pressure and microcirculation. In: Nimmi H, Xiu RJ, Sawada T, Zheng C. (eds). *Microcirculatory Approach to Asian Traditional Medicine*. New York: Elsevier Science, 1996, 131-8
127. Vittek J., Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. *Experientia* 1995 Sep 29;51(9-10):927-35, Department of Medicine, New York Medical College, Valhalla 10595, USA
128. Williamson, E. M. (2002). *Major Herbs of Ayurveda*, Churchill Livingstone, Nyarko AK, Asare-Anane H, Ofosuhen M, Addy ME, Teye K, Addo P., Aqueous extract of *Ocimum canum* decreases levels of fasting blood glucose and free radicals and increases antiatherogenic lipid levels in mice.
129. *Vascu Pharmacol*. 2002 Dec;39(6):273-9. Noguchi Memorial Institute for Medical Research, University of Ghana, P.O. Box LG 581, Legon, Accra, Ghana
130. Singh S; Rehan HM; Majumdar DK, Effect of *Ocimum sanctum* fixed oil on blood pressure, blood clotting time and pentobarbitone-induced sleeping time. *J Ethnopharmacol* 2001 Dec;78(2-3):139-43 College of Pharmacy, University of Delhi, Pushp Vihar, 110017, New Delhi, India
131. Fuhrman B, Volkova N, Kaplan M, Presser D, Attias J, Hayek T, Aviram M. Antiatherosclerotic effects of licorice extract supplementation on hypercholesterolemic patients: increased resistance of LDL to atherogenic modifications, reduced plasma lipid levels, and decreased systolic blood pressure. *Nutrition*. 18(3):268-73, 2002 March, Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, Haifa, Israel.

132. Asgary S, Naderi GH, Sarrafzadegan N, Mohammadifard N, Mostafavi S, Vakili R. Antihypertensive and antihyperlipidemic effects of *Achillea wilhelmsii*. *Drugs Exp. Opin. Res* 2000;26(3):89-93
133. Wang J, Xu J, Zhong JB. Effect of Radix notoginseng saponins on platelet activating molecule expression and aggregation in patients with blood hyperviscosity syndrome, *Zhongguo Zhong Xi Yi Jie He Za Zhi*. 2004 Apr;24(4):312-6. Xiyuan Hospital, China Academy of TCM, Beijing 100091. Wangjie@cast.org.cn
134. PDR for Nutritional Supplements 1st addition, 2001, *Medical Economics*, pg. 338-41
135. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. *J Am Coll Cardiol*. 1986;8:1245-1255.
136. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. *JAMA*. 1987;257:3233-3240.
137. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. *N Engl J Med*. 1990;323:1289-1298.
138. Grundy S, Vega G, McGovern M, et al. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. *Arch Intern Med* 2002;162:1568-76.
139. Adams MR, McCredie R, Jessup W, et al. Oral L-arginine improves endothelium-dependent dilation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. *Atherosclerosis*. 1997; 129:261-269.
140. Barbul A. Arginine: biochemistry, physiology, and therapeutic implications. *JPEN*. 1986; 10:227-238.
141. Chan JS, Boger RH, Bode-Boger SM. Et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. *Arterioscler Thromb Vasc Biol*. 2000; 20:1040-1046. *J Am Coll Cardiol* 2002;39:37-48.
142. Gordon A, et al. Creatine supplementation in chronic heart failure increases skeletal muscle, creatine phosphate and muscle performance. *Cardiovascular Research*, 1995, Vol. 30:3,413-418.
143. Ferraro, S., Codella, C., Palumbo, F., et al. Hemodynamic effects of creatine phosphate in patients with congestive heart failure; a double-blind comparison trial versus placebo. *Clin cardiol*, 1996, 19:(9), 699-703.
144. Stead LM, et al. Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. *Am J Physiol Endocrinol Metab* 2001 Nov;281(5):E1095-100.
145. Wyss M, Schulze A. Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? *Neuroscience*. 2002;112(2):243-60.
146. Brilla, L.R., FACSM, Giroux, M.S. Taylor, A. Kennedy, J. Ramierex, R.E. Puz, D. and Knutzen, K.M. FACSM. Magnesium-Creatine Supplementation on Total Body Water, ICF and ECF Compartments, Western Washington University, WA. American College Sports Medicine 2002.
147. Wischmeyer PE, Jayakar D, Williams U, Singleton KD, Riehm J, Bacha EA, Jeevanandam V, Christians U, Serkova N. Single dose of glutamine enhances myocardial tissue metabolism, glutathione content, and improves myocardial function after ischemia-reperfusion injury. *JPEN J Parenter Enteral Nutr*. 2003 Nov-Dec;27(6):396-403. Department of Anesthesiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA. paul.wischmeyer@UCHSC.edu
148. Khogali SE, Harper AA, Lyall JA, Rennie MJ. Effects of L-glutamine on post-ischaemic cardiac function: protection and rescue. *J Mol Cell Cardiol*. 1998 Apr;30(4):819-27.
149. Wischmeyer PE, Vanden Hoek TL, Li C, Shao Z, Ren H, Riehm J, Becker LB. Glutamine preserves cardiomyocyte viability and enhances recovery of contractile function after ischemia-reperfusion injury. *JPEN J Parenter Enteral Nutr*. 2003 Mar-Apr;27(2):116-22.
150. Khogali SE, Pringle SD, Weryk BV, Rennie MJ. Is glutamine beneficial in ischemic heart disease? *Nutrition*. 2002 Feb;18(2):123-6.
151. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. *Clin Ther*. 2003 May;25(5):1429-39. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. giuderosa@tin.it.
152. Kies, C., Driskell, J., *Sports Nutrition: Minerals and Electrolytes*. CRC Press Boca Raton, FL. 1995, pg. 200-203
153. Verma, S., Cam, M.C., and McNeill, J.H., Nutritional factors that favorably influence glucose/insulin system: vanadium, *J. AM. Coll. Nutr.*, 17,11,1998
154. Najla Guthrie, Elzbieta M. Kurowska, *Handbook of Nutraceuticals and Functional Foods*, CRC Press, Boca Raton, FL, Chapter 16, Anticancer and Cholesterol-lowering Actives of Tocotrienols pg. 269-80
155. Kallio H; Yang B; Peippo P; Tahvonen R; Pan R, *J Agric Food Chem* 2002 May 8;50(10):3004-9 (ISSN: 0021-8561) Department of Biochemistry and Food Chemistry, University of Turku, FIN-20014 Turku, Finland. heikki.kallio@utu.fi
156. Crane FL. Biochemical functions of Co Q 10. *J Amer Coll Nutri* 2001;20:591-98
157. Wu X, Beecher GR, Holden JM, Haytowitz DB, Gebhardt SE, Prior RL. Lipophilic and hydrophilic antioxidant
158. *Med*. 2004 Apr;10(2):235-9.

159. Aviles JM, Whelan SE, Hernke DA, Williams BA, Kenny KE, O'Fallon WM, Kopecky SL. Intercessory prayer and cardiovascular disease progression in a coronary care unit population: a randomized controlled trial. *Mayo Clin Proc.* 2001 Dec;76(12):1192-8.
160. Wilson PW, Abbott RD, Castelli WP. High-density lipoprotein cholesterol and mortality. The Framingham Heart Study. *Arteriosclerosis.* 1988 Nov-Dec;8(6):737-41. Framingham Epidemiology Research Section, NHLBI, Massachusetts.
161. Iribarren C, Reed DM, Chen R, Yano K, Dwyer JH. Low serum cholesterol and capacities of common foods in the United States. *J Agric Food Chem.* 2004 Jun 16;52(12):4026-37. Arkansas Children's Nutrition Center and Agricultural Research Service, U.S. Department of Agriculture, 1120 Marshall Street, Little Rock, Arkansas 72202, USA.
162. Laux MT, Aregullin M, Berry JP, Flanders JA, Rodriguez E. Identification of a p53-dependent pathway in the induction of apoptosis of human breast cancer cells by the natural product, resveratrol. *J Altern Complement mortality.* Which is the cause and which is the effect? *Circulation.* 1995 Nov 1;92(9):2396-403. Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles 90033, USA.
163. Harris T, Cook EF, Garrison R, Higgins M, Kannel W, Goldman L. Body mass index and mortality among nonsmoking older persons. The Framingham Heart Study. *AMA.* 1988 Mar 11;259(10):1520-4. National Center for Health Statistics, Hyattsville, Md 20782.
164. Sharp SJ, Pocock SJ. Time trends in serum cholesterol before cancer death. Medical Statistics Unit, London School of Hygiene and Tropical Medicine, United Kingdom. *Epidemiology.* 1997 Mar;8(2):132-6.
165. Schuit AJ, Van Dijk CE, Dekker JM, Schouten EG, Kok FJ. Am J Epidemiol. 1993 May 1;137(9):966-76. Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. Department of Epidemiology and Public Health, Agricultural University, Wageningen, The Netherlands.
166. Gaddi A, Descovich GC, Noseda G, Fragiaco C, Colombo L, Craveri A, Montanari G, Sirtori CR. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. *Atherosclerosis.* 1984 Jan;50(1):73-83.
167. Arsenio L, Bodria P, Magnati G, Strata A, Trovato R. Effectiveness of long-term treatment with pantethine in patients with dyslipidemia. *Clin Ther.* 1986;8(5):537-45.
168. Naruta E, Buko V. Hypolipidemic effect of pantothenic acid derivatives in mice with hypothalamic obesity induced by aurothioglucose. *Exp Toxicol Pathol.* 2001 Oct;53(5):393-8.
169. Sheps, D.S. et al. (2002). "New study says people take mental stress to heart." March 26: www.americanheart.org/presenter.jhtml?identifier=3001555
170. Losonczy, K.G. et al. (1996). "Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: The Established Populations for Epidemiologic Studies of the Elderly." *American Journal of Clinical Nutrition*; 64: 190-6.
171. Trinidad TP, Loyola AS, Mallillin AC, Valdez DH, Askali FC, Castillo JC, Resaba, RL, Masa DB. The cholesterol-lowering effect of coconut flakes in humans with moderately raised serum cholesterol. *J Med Food.* 2004 Summer;7(2):136-40. Department of Science and Technology, Food and Nutrition Research Institute, Bicutan, Taguig, MetroManila, 1631 Philippines. tpt@fnri.dost.gov.ph
172. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. *Pharmacoepidemiol Drug Saf.* 2004 Jul;13(7):417-26. Office of Drug Safety, Food and Drug Administration, Rockville, MD 20857, USA. changj@cdcr.fda.gov
173. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. *Circulation.* 2004 Jun 15;109(23 Suppl 1):III50-7. Department of Pharmacological Sciences, University of Milan, Milan, Italy.
174. Kaplan RC, Frishman WH, Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. *Heart Dis* 2001 Sep-Oct;3(5):326-32.
175. Blake GJ, Ridker PM, Kuntz KM, Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. *J Am Coll Cardiol* 2002 Jul 3;40(1):49-55.
176. Haruki Shimizu, Yutaka Kiyohara, Isao Kato, Takanari Kitazono, Yumihiro Tanizaki, Michiaki Kubo, Hirofumi Ueno, Setsuro Ibayashi, Masatoshi Fujishima, and Mitsuo Iida, Relationship Between Plasma Glutathione Levels and Cardiovascular Disease in a Defined Population: The Hisayama Study, *Stroke*, Sep 2004; 35: 2072 - 2077.
177. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. 2002;288:2569-2578.
178. Ravnskov U. The questionable role of saturated and polyunsaturated fatty acids in cardiovascular disease. 1998; 51:443-460.
179. Hooper L, Summerbell CD, Higgins JPT, Thompson R, Capps NE, Davey Smith G, et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. 2001;322:757-763.
180. Ravnskov U. Diet-heart disease hypothesis is wishful thinking. 2002;324:238. *JAMA J Clin Epidemiol* BMJ BMJ 2 3 4
181. Spiller GA, Miller A, Olivera K, et al. Effects of plant-based diets high in raw or roasted almonds, or roasted almond butter on serum lipoproteins in humans. *J Am Coll Nutr.* 2003 Jun;22(3):195-200.

182. Sabate J, Haddad E, Tanzman JS, Jambazian P, Rajaram S. Serum lipid response to the graduated enrichment of a Step I diet with almonds: a randomized feeding trial. *Am J Clin Nutr.* 2003 Jun;77(6):1379-84.
183. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *JAMA.* 1996 Sep 18;276(11):875-81.
184. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. *JAMA.* 1996 Sep 18;276(11):882-88.
185. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study. *Circulation.* 1997 Jan 7;95(1):69-75.
186. Kuller L, Tracy P, Arnold A, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. *Arterioscler Thromb Vasc Biol.* 2002 Jul 1;22(7):1175-80.
187. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA.* 2001 May 16;285(19):2486-97.
188. Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. *J Am Coll Cardiol.* 2004 Mar 3;43(5):717-24.
189. van Lennep JE, Westerveld HT, Van Lennep HW, Zwinderman AH, Erkelens DW, van der Wall EE. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. *Arterioscler Thromb Vasc Biol.* 2000 Nov;20(11):2408-13.
190. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA.* 2002 Jan 16;287(3):356-9.
191. Taylor AJ, Merz CN, Udelson JE. 34th Bethesda Conference: "Can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease?" *J Amer Coll Cardiol.* 2003 Jun 4;(11)41:1860-2.
192. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. *Nat Med.* 2004 Nov 07
193. Yamamoto M, Kumagai A, Yamamura Y. Plasma lipid-lowering and lipogenesis-stimulating actions of ginseng saponins in tumor-bearing rats. *Am J Chin Med.* 1983;11(1-4):88-95.
194. Yamamoto M, Kumagai A, Yamamura Y. Plasma lipid-lowering action of ginseng saponins and mechanism of the action. *Am J Chin Med.* 1983;11(1-4):84-7.
195. Yokozawa T, Kobayashi T, Kawai A, Oura H, Kawashima Y. Hyperlipemia-improving effects of ginsenoside-Rb2 in cholesterol-fed rats. *Chem Pharm Bull (Tokyo).* 1985 Feb;33(2):722-9.
196. Park KH, Shin HJ, Song YB, Hyun HC, Cho HJ, Ham HS, Yoo YB, Ko YC, Jun WT, Park HJ. Possible role of ginsenoside Rb1 on regulation of rat liver triglycerides. *Biol Pharm Bull.* 2002 Apr;25(4):457-60.
197. Yamamoto M, Uemura T, Nakama S, Uemiyama M, Kumagai A. Serum HDL-cholesterol-increasing and fatty liver-improving actions of Panax ginseng in high cholesterol diet-fed rats with clinical effect on hyperlipidemia in man. *Am J Chin Med.* 1983;11(1-4):96-101.
198. Gustafsson M, Flood C, Jirholt P, Boren J. Retention of atherogenic lipoproteins in atherogenesis. *Cell Mol Life Sci.* 2004 Jan;61(1):4-9.
199. Cabezas Castro M, Liem A. The use of apolipoprotein B in clinical practice to determine the risk for atherosclerosis. *Ned Tijdschr Geneesk.* 2003 Jul 26;147(30):1445-8.
200. Walldius G, Jungner I. Apolipoproteins are new and better risk indicators of myocardial infarction. *Lakartidningen.* 2004 Mar 25;101(13):1188-94.
201. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. *J Intern Med.* 2004 Feb;255(2):188-205.
202. Williams K, Sniderman AD, Sattar N, D'Agostino R Jr, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation.* 2003 Nov 11;108(19):2312-6.
203. Ruf JC. Alcohol, wine and platelet function., *Biol Res.* 2004;37(2):209-15.
204. Freedman, Jane, Drinking Concord grape juice significantly increased good cholesterol and significantly lowered two markers of inflammation in people with stable coronary artery disease, November, 2004 *Journal Arteriosclerosis, Thrombosis and Vascular Biology*, Boston University School of Medicine.

205. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. *Am J Med.* 2004 Dec 1;117(11):823-9.
206. Rifai N, Ridker PM, Inflammatory markers and coronary heart disease. *Curr Opin Lipidol* 2002 Aug;13(4):383-9.
207. Albert CM, et al, Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation* 2002 Jun 4;105, (22):2595-9.
208. Bermudez EA, Ridker PM, C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. *Prev Cardiol* 2002 Winter;5(1):42-6.
209. Blake GJ, Ridker PM, Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. *Ital Heart J* 2001 Nov;2(11):796-800.
210. Agmon Y, Khandheria BK, Meissner I, Petterson TM, O'Fallon WM, Wiebers DO, Christianson TJ, McConnell JP, Whisnant JP, Seward JB, Tajik AJ. C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study. *Arch Intern Med.* 2004 Sep 13;164(16):1781-7.
211. Rifai N, et al, C-reactive protein and coronary heart disease. *Cardiovasc Toxicol* 2001;1(2):153-7.
212. Jialal I, Devaraj S, Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. *Am J Clin Pathol* 2001 Dec;116 Suppl:S108
213. Zairis M, et al, C-reactive protein and multiple complex coronary artery plaques in patients with primary unstable angina. *Atherosclerosis* 2002 Oct;164(2):355.
214. Lowe GD, The relationship between infection, inflammation, and cardiovascular disease: an overview. *Ann Periodontol* 2001 Dec;6(1):1-8
215. Kaplan RC, Frishman WH, Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. *Heart Dis* 2001 Sep-Oct;3(5):326-32.
216. Blake GJ, Ridker PM, Kuntz KM, Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. *J Am Coll Cardiol* 2002 Jul 3;40(1):49-55.
217. Devaraj S, Jialal I, Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6, levels in normal volunteers and type 2 diabetic patients. *Free Radic Biol Med* 2000 Oct 15;29(8):790-2.
218. Patrick L, Uzick M, Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. *Altern Med Rev* 2001 Jun;6(3):248-71
219. Devaraj S, Jialal I, Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. *Free Radic Biol Med* 2000 Oct 15;29(8):790-2.
220. Patrick L, Uzick M, Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. *Altern Med Rev* 2001 Jun;6(3):248-71
221. Nestel P, et al, The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. *Am J Clin Nutr* 2002, Aug;76(2):326-30.
222. Fraser DA, et al, Serum levels of interleukin-6 and dehydroepiandrosterone sulphate in response to either fasting or a ketogenic diet in rheumatoid arthritis patients. *Clin Exp Rheumatol* 2000 May-Jun;18(3):357-62
223. LM, Giddens K, McInerney MM, McQueen MJ, Nassar BA. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. *J Am Coll Cardiol.* 2003 Nov 19;42(10):1747-53, *J Am Coll Cardiol.* 2003 Nov 19;42(10):1754-6. Division of Cardiology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. ltittle@dal.ca
224. Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, Dagenais GR. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. *Circulation.* 2004 Aug 24;110(8):934-9. Epub 2004 Aug 09. Quebec Heart Institute/Laval Hospital, Laval University, 2725 Chemin Ste-Foy, Quebec City, Quebec, Canada G1V 4G5. peter.Bogaty@med.ulaval.ca
225. Won E, Won J, Kwon S, Lee Y, Nam T, Ahn D. Testosterone causes simultaneous decrease of [Ca²⁺]_i and tension in rabbit coronary arteries: by opening voltage dependent potassium channels. *Yonsei Med J.* 2003 Dec 30; 44(6): 1027-33.
226. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. *J Endocrinol.* 2003 Sep; 178(3): 373-80.

227. Dobrzycki S, Serwatka W, Nadlewski S, Korecki J, Jackowski R, Paruk J, Ladny JR, Hirnle T. An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. *J Med Invest*. 2003 Aug; 50(3-4): 162-9.
228. Tagawa, N., Takano, T., Fukata, S. et al. Serum concentration of androstenediol and androstenediol sulfate in patients with hyperthyroidism and hypothyroidism. *Endocr. J*. 2001 Jun; 48(3): 345-54.
229. Tagawa, N., Tamanaka, J., Fujinami, A. et al. Serum dehydroepiandrosterone, dehydroepiandrosterone sulfate, and pregnenolone sulfate concentrations in patients with hyperthyroidism and hypothyroidism. *Clin. Chem*. 2000 Apr; 46(4): 523-8.
230. Aronow WS, et al. 2000. Increased plasma homocysteine is an independent predictor of new coronary events in older persons. *Am J Cardiol* 86:346-7
231. Austin RC, et al. 1998. Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. Homocysteine and H₂O₂ act synergistically to enhance mitochondrial damage. *J Biol Chem* 273(46):30808-17
232. Appel LJ, et al. 2000. Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. *Circulation* 102:852-57. DeRose DJ, et al. 2000. Vegan diet-based lifestyle program rapidly lowers homocysteine levels. *Prev Med* 30:225-33
233. Mayer O Jr., Simon J, Rosolova H, et al, *Eur J Clin Pharmacol*, 2002;58:1-5, (Address: Otto Mayer Jr, (FAX) +420-19-7423022, E-mail: mayerjr@lfp.cuni.cz) 39630
234. Misra A, Vikram NK, Pandey RM, Dwivedi M, Ahmad FU, Luthra K, Jain K, Khanna N, Devi JR, Sharma R, Guleria R. Hyperhomocysteinemia, and low intakes of folic acid and vitamin B12 in urban North India. *Eur J Nutr*. 2002 Apr;41(2):68-77. Department of Medicine, All India Institute of Medical Sciences, New Delhi.
235. Hirano K, et al. 1994. Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. *Free Radic Res* 21:267-76
236. Wald, Dr. David, Lowering Homocysteine With Folic Acid Decreases Cardiovascular Disease Risk, *BMJ* Nov. 2002;325:1202-1206.
237. Hankey GJ, Eikelboom JW. Homocysteine and stroke. *Lancet*. 2005 Jan 15;365(9455):194-6.
238. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. *Lancet*. 2005 Jan 15;365(9455):224-32.
239. Abidov M, Grachev S, Seifulla RD, Ziegenfuss TN. Extract of *Rhodiola rosea* radix reduces the level of C-reactive protein and creatinine kinase in the blood. *Bull Exp Biol Med*. 2004 Jul;138(1):63-4.
240. A team from the Institute of Nutraceuticals and Functional Foods at Laval University in Québec Changing to Med diet improves cholesterol levels, *Journal of Nutrition*, March, 2005, (135:410-415).
241. Boger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA a novel cardiovascular risk factor. *Altern Med Rev*. 2005 Mar;10(1):14-23. Professor and Head, Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg-Eppendorf, Germany. Correspondence address: Martinistr. 52, D-20246 Hamburg, Germany. E-mail: boeger@uke.uni-hamburg.de.
242. Cakir E, Ozcan O, Yaman H, Akgul EO, Bilgi C, Erbil MK, Yesilova Z. Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients. *J Clin Endocrinol Metab*. 2005 Mar;90(3):1651-4. Epub 2004 Dec 21. Department of Emergency Medicine, Gulhane Military Medical School, 06010, Etilik, Ankara, Turkey. erdcakir@yahoo.com
243. Sher L, Type D personality: the heart, stress, and cortisol. *QJM*. 2005 May;98(5):323-9.
244. Grippo AJ, Francis J, Beltz TG, Felder RB, Johnson AK. Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia. *Physiol Behav*. 2005 Apr 13;84(5):697-706.
245. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. *Pharmacotherapy*. 2003 Dec;23(12):1663-7.
246. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. *Pharmacotherapy*. 2003 Jul;23(7):871-80.
247. Muck AO, Seeger H, Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. *Int J Clin Pharmacol Ther*. 2004 Dec;42(12):695-700.
248. Khurana, Dr. Vikas Statins May Significantly Reduce Breast Cancer Risk: Case-Control Study, Reuters Health Information May 25, 2005. Louisiana State University Health Science Center in Shreveport
249. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. *J Urol*. 2005 Jun;173(6):1923-5.

250. Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, Lipson SF, Ellison PT, Thune I. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. *Cancer Epidemiol Biomarkers Prev.* 2005 Jan;14(1):33-40. Institute of Community Medicine, Faculty of Medicine, University of Tromso, N-9037 Tromso, Norway.
251. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. *J Clin Invest.* 2005 Apr;115(4):959-68. Epub 2005 Mar 17. The Urological Diseases Research Center, Department of Urology, Children's Hospital Boston, Boston, Massachusetts 02115, USA.
252. Brown, David *Washington Post* August 9, 2001; Page A01
253. Christoph Wanner, M.D., Vera Krane, M.D., Winfried März, M.D., Manfred Olschewski, M.Sc., Johannes F.E. Mann, M.D., Günther Ruf, M.D., Eberhard Ritz, M.D., for the German Diabetes and Dialysis Study Investigators, Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis, *New England J. of Medicine*, Volume 353:238-248, July 21, 2005 Number 3.
254. Nut link to lower cholesterol gains credence, *Journal of Nutrition*, 08/09/2005, North-West University in Potchefstroom, South Africa.
255. Schubert CM, Rogers NL, Remsberg KE, Sun SS, Chumlea WC, Demerath EW, Czerwinski SA, Towne B, Siervogel RM. Lipids, lipoproteins, lifestyle, adiposity and fat-free mass during middle age: the Fels Longitudinal Study. *Int J Obes (Lond).* 2006 Feb;30(2):251-60.
256. Ran XW, Li XS, Tong NW, Li QF, Tang BD, Li XL. [Body fat distribution: its characteristics and relationship to cardiovascular risk factors in obese Chinese] *Sichuan Da Xue Xue Bao Yi Xue Ban.* 2004 Sep;35(5):699-703.
257. Hu D, Hannah J, Gray RS, Jablonski KA, Henderson JA, Robbins DC, Lee ET, Welty TK, Howard BV. Effects of obesity and body fat distribution on lipids and lipoproteins in nondiabetic American Indians: The Strong Heart Study. *Obes Res.* 2000 Sep;8(6):411-21.
258. Peschel D, Koerting R, Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. *J Nutr Biochem.* 2006 May 16.
259. Kathryn M. Rexrode, M.D., M.P.H., associate physician and internist, Harvard Medical School and Brigham and Women's Hospital, Boston; Gail Frank, D.P.H., R.D., professor of nutrition, California State University, Long Beach, Calif.; Jan. 17, 2001, *Journal of the American Medical Association*; February 1997 *Arteriosclerosis, Thrombosis and Vascular Biology*
260. Sidika E. Kasim-Karakas, *Handbook of Nutraceuticals and Functional Foods*, CRC Press, Boca Raton, FL. 2001 Chapter 18, Omega-3 Fish Oils and Lipoprotein Metabolism pg. 295-303
261. Nestel P, Shige H, Pomeroy S, et al, *Am J Clin Nutr*, 2002;76:326-330. (Address: Paul Nestel, E-mail: paul.nestel@baker.edu.au) 39662
262. Erkkila, A. Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. *Am J Clin Nutr*, 2004;80:626-32
263. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. n-3 Fatty acids from fish or fish-oil supplements, but not {alpha}-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. *Am J Clin Nutr.* 2006 Jul;84(1):5-17.
264. Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. *Circulation.* 2005 Sep 27;112(13):1945-52. Epub 2005 Sep 19.
265. Schroeksnadel K, Frick B, Winkler C, Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. *Curr Vasc Pharmacol.* 2006 Jul;4(3):205-13.
266. Bursill CA, Abbey M, Roach PD. A green tea extract lowers plasma cholesterol by inhibiting cholesterol synthesis and upregulating the LDL receptor in the cholesterol-fed rabbit. *Atherosclerosis.* 2006 Sep 11.
267. Tivesten A, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, Fagerberg B. Circulating Estradiol is an Independent Predictor of Progression of Carotid Artery Intima-Media Thickness in Middle-Aged Men. *J Clin Endocrinol Metab.* 2006 Aug 29.
268. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. *Circulation.* 2004 May 4;109(17):2074-9. Epub 2004 Apr 19.
269. Hougaku H, Fleg JL, Najjar SS, Lakatta EG, Harman SM, Blackman MR, Metter EJ. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. *Am J Physiol Endocrinol Metab.* 2006 Feb;290(2):E234-42. Epub 2005 Sep 13.

270. Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, Mercurio G, Volterrani M, Aversa A, Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina, Int J Impot Res. 2006 Aug 31.
271. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and Vegetable Consumption and Risk of Coronary Heart Disease: A Meta-Analysis of Cohort Studies. J Nutr. 2006 Oct;136(10):2588-2593
272. Adams MR, Golden DL, Chen H, Register TC, Gugger ET. A diet rich in green and yellow vegetables inhibits atherosclerosis in mice. J Nutr. 2006 Jul;136(7):1886-9.
273. Ajani UA, Ford ES, McGuire LC. Distribution of lifestyle and emerging risk factors by 10-year risk for coronary heart disease, Eur J Cardiovasc Prev Rehabil. 2006 Oct;13(5):745-52.
274. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994 Jun 11;343(8911):1454-9. Erratum in: Lancet 1995 Mar 18;345(8951):738.
275. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999 Feb 16;99(6):779-85
276. Renaud S, de Lorgeril M, Delaye J, Guidollet J, Jacquard F, Mamelle N, Martin JL, Monjaud I, Salen P, Toubol P. Cretan Mediterranean diet for prevention of coronary heart disease. Am J Clin Nutr. 1995 Jun;61(6 Suppl):1360S-1367S.
277. Trichopoulou A, Bamia C, Trichopoulos D. Mediterranean diet and survival among patients with coronary heart disease in Greece. Arch Intern Med. 2005 Apr 25;165(8):929-35.
278. Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, Berry EM. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet. 2002 Nov 9;360(9344):1455-61.
279. de Lorgeril M, Salen P, Martin JL, Monjaud I, Boucher P, Mamelle N. Mediterranean dietary pattern in a randomized trial: prolonged survival and possible reduced cancer rate. Arch Intern Med. 1998 Jun 8;158(11):1181-7)
280. Knuops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, van Staveren WA. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004 Sep 22;292(12):1433-9.
281. The GISSI-prevenzione (Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Eur J Heart Fail. 2005 Aug;7(5):904-9.] trial showed significant benefit with concentrated omega-3 fatty acids (fish oil), an ARR benefit similar to statins.
282. Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, Mercurio G, Volterrani M, Aversa A, Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res. 2006 Aug 31
283. Tivesten A, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, Fagerberg B. Circulating Estradiol is an Independent Predictor of Progression of Carotid Artery Intima-Media Thickness in Middle-Aged Men. J Clin Endocrinol Metab. 2006 Aug 29
284. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004 May 4;109(17):2074-9. Epub 2004 Apr 19. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
285. Houngaku H, Fleg JL, Najjar SS, Lakatta EG, Harman SM, Blackman MR, Metter EJ. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab. 2006 Feb;290(2):E234-42. Epub 2005 Sep 13. Clinical Research Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21225, USA.
286. Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, Mercurio G, Volterrani M, Aversa A, Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina, Int J Impot Res. 2006 Aug 31;
287. Cakir E, Ozcan O, Yaman H, Akgul EO, Bilgi C, Erbil MK, Yesilova Z. Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic

- hypogonadotropic hypogonadism patients. *J Clin Endocrinol Metab.* 2005 Mar;90(3):1651-4. Epub 2004 Dec 21.
288. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. *J Clin Oncol.* 2006 Aug 20;24(24):3979-83.
289. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. *Arch Intern Med.* 2006 Aug 14-28;166(15):1660-5.
290. Gyllenberg J, Rasmussen SL, Borch-Johnsen K, Heitmann BL, Skakkebaek NE, Juul A. Cardiovascular risk factors in men: The role of gonadal steroids and sex hormone-binding globulin. *Metabolism.* 2001 Aug;50(8):882-8.
291. Dunajska K, Milewicz A, Szymczak J, Jedrzejuk D, Kuliczkowski W, Salomon P, Nowicki P. Evaluation of sex hormone levels and some metabolic factors in men with coronary atherosclerosis. *Aging Male.* 2004 Sep;7(3):197-204.
292. Reinecke H, Bogdanski J, Woltering A, Breithardt G, Assmann G, Kerber S, von Eckardstein A. Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women. *Am J Cardiol.* 2002 Aug 15;90(4):364-8.
293. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. *J Nutr.* 2006 Oct;136(10):2588-93.
294. Antoniadou C, Tousoulis D, Marinou K, Vasiliadou C, Tentolouris C, Bouras G, Pitsavos C, Stefanadis C. Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. *Am J Clin Nutr.* 2006 Oct;84(4):781-8.
295. Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. *Biofactors.* 2005;25(1-4):147-52
296. Iribarren, Carlos, Darbinian, Jeanne A. Lo, Joan C., Fireman, Bruce H., Go, Alan S., Value of the Sagittal Abdominal Diameter in Coronary Heart Disease Risk Assessment: Cohort Study in a Large, Multiethnic Population, *American Journal of Epidemiology* 2006 164(12):1150-1159; doi:10.1093/aje/kwj341
297. Schaefer, EJ, LDL Particle Number, Not Size, a Significant Predictor of CVD Risk, *AHA 2004 Scientific Sessions: Abstract 3583.* Presented Nov. 8, 2004. *Medscape Medical News* 2004. © 2004 Medscape
298. Castilla P, Echarri R, Dávalos A, Cerrato F, Ortega H, Teruel JL, Lucas MF, Gómez-Coronado D, Ortuño J, Lasunción MA. Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. *Am J Clin Nutr.* 2006 Jul;84(1):252-62.
299. Campolo J, De Maria R, Caruso R, Accinni R, Turazza F, Parolini M, Roubina E, De Chiara B, Cighetti G, Frigerio M, Vitali E, Parodi O. Blood glutathione as independent marker of lipid peroxidation in heart failure. *Int J Cardiol.* 2007 Apr 12;117(1):45-50. Epub 2006 Aug 1.
300. Campolo J, Caruso R, De Maria R, Parolini M, Oliva F, Roubina E, Cighetti G, Frigerio M, Vitali E, Parodi O. Aminothioliol redox alterations in patients with chronic heart failure of ischaemic or non-ischaemic origin. *J Cardiovasc Med (Hagerstown).* 2007 Dec;8(12):1024-1028.
301. Shen BJ, Avivi YE, Todaro FJ, et al., Anxiety Characteristics Independently and Prospectively Predict Myocardial Infarction in Men: The Unique Contribution of Anxiety Among Psychologic Factors, *J Am Coll Cardiol.* 2008;51:113-119, 1/7/2008.
302. Hong-Liang Li, C. Liu, G. de Couto, M. Ouzounian, M. Sun, A.-B. Wang, Y. Huang, C.-W. He, Y. Shi, X. Chen, M.P. Nghiem, Y. Liu, M. Chen, F. Dawood, M. Fukuoka, Y. Maekawa, L. Zhang, A. Leask, A.K. Ghosh, L.A. Kirshenbaum, P.P. Liu, "*Curcumin prevents and reverses murine cardiac hypertrophy*" *Journal of Clinical Investigation*, Available online, Free Access, doi: 10.1172/JCI32865, 2/2008
303. T. Morimoto, Y. Sunagawa, T. Kawamura, T. Takaya, H. Wada, A. Nagasawa, M. Komeda, M. Fujita, A. Shimatsu, T. Kita, K. Hasegawa, "*The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats*" *Journal of Clinical Investigation* Available online, Free Access, doi: 10.1172/JCI33160, 2/2008
304. Maslov LN, Platonov AA, Arbuzov AG, Burkova VN, Naryzhnaia NV. The complex adaptogenic drug tonizid attenuates myocardial contractile dysfunction and prevents irreversible cardiomyocytic damages in ischemia and reperfusion of the isolated heart, *Patol Fiziol Eksp Ter.* 2007 Jan-Mar;(1):14-7. Russian.
305. No author [Complex adaptogen drug tonizid attenuates myocardial contractility dysfunction and prevents the appearance of irreversible cardiomyocyte damage during ischemia and reperfusion in isolated heart] *Eksp Klin Farmakol.* 2008 May-Jun;71(3):15-22

306. Bundy R., et al., Artichoke leaf extract (*Cynara scolymus*) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomised double-blind placebo controlled trial. *Phytomedicine* (2008), doi:10.1016/j.phymed.2008.03.001
307. Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008 Aug 29
308. Velavan P, Loh PH, Clark A, Cleland JG. Is the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) the answer to the cholesterol paradox in heart failure? *Congest Heart Fail*. 2008 Jan-Feb;14(1):55
309. Velavan P, Loh PH, Clark A, Cleland JG. Is the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) the answer to the cholesterol paradox in heart failure? *Congest Heart Fail*. 2008 Jan-Feb;14(1):55.
310. Plaisance EP, Mestek ML, Mahurin AJ, Taylor JK, Moncada-Jimenez J, Grandjean PW. Postprandial triglyceride responses to aerobic exercise and extended-release niacin. *American Journal of Clinical Nutrition* 2008;88:30–7.
311. Becker DJ, Gordon RY, Morris PB, Yorko J, Gordon YJ, Li M, Iqbal N. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. *Mayo Clin Proc*. 2008 Jul;83(7):758-64.
312. Lerman RH, Minich DM, Darland G, Lamb JJ, Schiltz B, Babish JG, Bland JS, Tripp ML Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial. *Nutr Metab (Lond)*. 2008 Nov 4;5(1):29.
313. Chahal HS, Drake WM. The endocrine system and ageing. *J Pathol*. 2007 Jan;211(2):173-80
314. Lamberts SW, van den Beld AW, van der Lely AJ: The endocrinology of aging. *Science* 1997; **278**: 419–424.
315. Liu PY, Death AK, Handelsman DJ: Androgens and cardio-vascular disease. *Endocr Rev* 2003; **24**: 313–340.
316. Tannenbaum C, Barrett-Connor E, Laughlin GA, Platt RW: A longitudinal study of dehydroepiandrosterone sulphate (DHEAS) change in older men and women: the Rancho Bernardo Study. *Eur J Endocrinol* 2004; **151**: 717–725.
317. Liu PY, Death AK, Handelsman DJ: Androgens and cardio-vascular disease. *Endocr Rev* 2003; **24**: 313–340.
318. Haffner SM, Moss SE, Klein BE, Klein R: Sex hormones and DHEA-SO₄ in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Diabetes Care* 1996; **19**: 1045–1050.
319. Bernini GP, Sgro' M, Moretti A, et al: Endogenous androgens and carotid intimal-medial thickness in women. *J Clin Endocrinol Metab* 1999; **84**: 2008–2012.
320. Santoro N, Torrens J, Crawford S, et al: Correlates of circulating androgens in mid-life women: the study of women's health across the nation. *J Clin Endocrinol Metab* 2005; **90**: 4836–4845.
321. Barna I, Feher T, de Chatel R: Relationship between blood pressure variability and serum dehydroepiandrosterone sulfate levels. *Am J Hypertens* 1998; **11**: 532–538.
322. M. Ledochowski, C. Murr, M. Jäger, D. Fuchs, Dehydroepiandrosterone, ageing, and immune activation, (2001) 1739–1747
323. S.S.C. Yen, G.A. Laughlin, Aging and the adrenal cortex, *Exp. Gerontol*. 33 (1998) 897–910
324. Seely D, Singh R. Adaptogenic potential of a polyherbal natural health product: report on a longitudinal clinical trial. *Evid Based Complement Alternat Med*. 2007 Sep;4(3):375-80
325. Torpy DJ, Chrousos GP. The three-way interactions between the hypothalamic-pituitary-adrenal and gonadal axes and the immune system. *Baillieres Clin Rheumatol*. 1996 May;10(2):181-98
326. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. *J Psychosom Res*. 2002 Oct;53(4):865-71
327. Seely D, Singh R. Adaptogenic potential of a polyherbal natural health product: report on a longitudinal clinical trial. *Evid Based Complement Alternat Med*. 2007 Sep;4(3):375-80
328. Torpy DJ, Chrousos GP. The three-way interactions between the hypothalamic-pituitary-adrenal and gonadal axes and the immune system. *Baillieres Clin Rheumatol*. 1996 May;10(2):181-98
329. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. *J Psychosom Res*. 2002 Oct;53(4):865-71
330. Lishmanov IuB, Maslov LN, Arbuzov AG, Krylatov AV, Platonov AA, Burkova VN, Kaiumova EA, Cardioprotective, inotropic, and anti-arrhythmia properties of a complex adaptogen "Tonizid" *Eksp Klin Farmakol*. 2008 May-Jun;71(3):15-22.

331. Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Fong DY, Tam S, Lau CP, Tse HF. Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. *Eur Heart J*. 2008 Sep 23
332. Acevedo M, Foody JM, Pearce GL, Sprecher DL. Fibrinogen: associations with cardiovascular events in an outpatient clinic. *Am Heart J*. 2002 Feb;143(2):277-82.
333. Green D, Foiles N, Chan C, Schreiner PJ, Liu K. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: The CARDIA Study. *Atherosclerosis*. 2008 Jul 2
334. Berger A, Rein D, Kratky E, Monnard I, Hajjaj H, Meirim I, Piguet-Welsch C, Hauser J, Mace K, Niederberger P. Cholesterol-lowering properties of *Ganoderma lucidum* in vitro, ex vivo, and in hamsters and minipigs. *Lipids Health Dis*. 2004 Feb 18;3(1):2.
335. Shang CH, Zhu F, Li N, Ou-Yang X, Shi L, Zhao MW, Li YX. Cloning and Characterization of a Gene Encoding HMG-CoA Reductase from *Ganoderma lucidum* and Its Functional Identification in Yeast. *Biosci Biotechnol Biochem*. 2008 May
336. Komoda Y, Shimizu M, Sonoda Y, Sato Y. Ganoderic acid and its derivatives as cholesterol synthesis inhibitors. *Chem Pharm Bull (Tokyo)*. 1989 Feb;37(2):531-3.
337. Lasukova TV, Arbuzov AG, Maslov LN, Burkova VN. *Ganoderma lucidum* extract in cardiac diastolic dysfunction and irreversible cardiomyocytic damage in ischemia and reperfusion of the isolated heart, *Patol Fiziol Eksp Ter*. 2008 Jan-Mar;(1):22-5.
338. Lin JF, Lin SM, Chih CL, Nien MW, Su HH, Hu BR, Huang SS, Tsai SK. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. *Life Sci*. 2008 Aug 29;83(9-10):313-7. Epub 2008 Jun 27.
339. <http://www.naturalnews.com/025058.html> , from Fraunfelder FW, Richards AB., Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. *Ophthalmology*. 2008 Dec;115(12):2282-5. Epub 2008 Oct 18.
340. Sood A, Arora R, Vitamin D Deficiency and Its Correlations With Increased Cardiovascular Incidences, *Am J Ther*. 2009 May 15.
341. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. *Mol Biotechnol*. 2007 Sep;37(1):31-7. Review.
342. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM; Chinese Coronary Secondary Prevention Study Group, Li S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. *Am J Cardiol*. 2008 Jun 15;101(12):1689-93. Epub 2008 Apr 11.
343. Ye P, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC; CCSPS Investigators. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study. *J Am Geriatr Soc*. 2007 Jul;55(7):1015-22.
344. Li JJ, Lu ZL, Kou WR, Chen Z, Wu YF, Yu XH, Zhao YC; on behalf of the Chinese Coronary Secondary Prevention Study Group. J Clin Pharmacol. 2009 Aug;49(8):947-956. Beneficial Impact of Xuezhikang on Cardiovascular Events and Mortality in Elderly Hypertensive Patients With Previous Myocardial Infarction From the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol. 2009 Aug;49(8):947-956.
345. Yin R, Li X, Song M, Wang H., Study of effects of procyanidin on the pathway of PPARgamma-NFkappaB of thoracic aorta of hyperlipemia rats, *Wei Sheng Yan Jiu*. 2009 Jul;38(4):472-5.
346. Humphrey LL, Fu R, Buckley DI, Freeman M, Helfand M. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. *J Gen Intern Med*. 2008 Dec;23(12):2079-86. Epub 2008 Sep 20.
347. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2009 Oct 6;151(7):483-95.
348. Chang ST, Chu CM, Hsu JT, Chung CM, Pan KL, Hsiao JF, Lin YS. Scrutiny of cardiovascular risk factors by assessing arterial stiffness in erectile dysfunction patients, *World J Urol*. 2009 Nov 5.
349. Chew KK, Finn J, Stuckey B, Gibson N, Sanfilippo F, Bremner A, Thompson P, Hobbs M, Jamrozik K. Erectile Dysfunction as a Predictor for Subsequent Atherosclerotic Cardiovascular Events: Findings from a Linked-Data Study. *J Sex Med*. 2009 Nov 13
350. LINDA L. HUMPHREY, MD, MPH; RONGWEI FU, PHD; KEVIN ROGERS, MD; MICHELE FREEMAN, MPH; AND MARK HELFAND, MD, MPH, Homocysteine Level and Coronary Heart

- Disease Incidence: A Systematic Review and Meta-analysis, *Mayo Clin Proc.* 2008;83(11):1203-1212
351. Kurowska EM, Spence JD, Jordan J, Wetmore S, Freeman DJ, Piché LA, Serratore P. HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia., *Am J Clin Nutr.* 2000 Nov;72(5):1095-100.
352. Mercanligil SM, Arslan P, Alasalvar C, Okut E, Akgül E, Pinar A, Geyik PO, Tokgözoğlu L, Shahidi F. Effects of hazelnut-enriched diet on plasma cholesterol and lipoprotein profiles in hypercholesterolemic adult men. *Eur J Clin Nutr.* 2007 Feb;61(2):212-20. Epub 2006 Sep 13.
353. Kaushik M, Sontineni SP, Hunter C. Cardiovascular disease and androgens: A review. *Int J Cardiol.* 2009 Nov 16.
354. Ramesh E, Geraldine P, Thomas PA. Regulatory effect of epigallocatechin gallate on the expression of C-reactive protein and other inflammatory markers in an experimental model of atherosclerosis, *Chem Biol Interact.* 2009 Sep 24.
355. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. *J Am Soc Nephrol.* 2009 Feb;20(2):397-404. Serum phosphorus levels associate with coronary atherosclerosis in young adults. Epub 2008 Nov 5.
356. Tuttle KR, Short RA. Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function. *Clin J Am Soc Nephrol.* 2009 Dec;4(12):1968-73. Epub 2009 Nov 5.